(Favezelimab)Biosimilar Reference Antibody-GS40260

货号：GS40260

Favezelimab (development code MK-4280) is an investigational, humanized monoclonal IgG4 antibody being developed for cancer immunotherapy. It functions as an antagonist of the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. By binding with high affinity to LAG-3 on the surface of T cells and other immune cells, favezelimab blocks its interaction with major histocompatibility complex class II (MHC-II) molecules and other potential ligands. This blockade releases the inhibitory "brake" that LAG-3 imposes on T-cell activation, proliferation, and effector function, thereby aiming to restore and enhance anti-tumor immune responses, particularly in T cells that are exhausted or dysfunctional. Its IgG4 isotype is chosen to minimize effector functions that could deplete immune cells.